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AbsTrACT
Objective in 2014, the european society of 
cardiology (esc) recommended the use of a novel 
risk prediction model (hcM risk-scD) to guide use 
of implantable cardioverter defibrillators (icD) for the 
primary prevention of sudden cardiac death (scD) in 
patients with hypertrophic cardiomyopathy (hcM). 
We sought to determine the performance of hcM 
risk-scD by conducting a systematic review and 
meta-analysis of articles reporting on the prevalence 
of scD within 5 years of evaluation in low, 
intermediate and high-risk patients as defined by the 
2014 guidelines (predicted risk <4%, 4%–<6% and 
≥6%, respectively).
Methods the protocol was registered with 
PrOsPerO (registration number: crD42017064203). 
MeDline and manual searches for papers published 
from October 2014 to December 2017 were 
performed. longitudinal, observational cohorts of 
unselected adult patients, without history of cardiac 
arrest were considered. the original hcM risk-scD 
development study was included a priori. Data were 
pooled using a random effects model.
results six (0.9%) out of 653 independent 
publications identified by the initial search were 
included. the calculated 5-year risk of scD was 
reported in 7291 individuals (70% low, 15% 
intermediate; 15% high risk) with 184 (2.5%) scD 
endpoints within 5 years of baseline evaluation. Most 
scD endpoints (68%) occurred in patients with an 
estimated 5-year risk of ≥4% who formed 30% of the 
total study cohort. Using the random effects method, 
the pooled prevalence of scD endpoints was 1.01% 
(95% ci 0.52 to 1.61) in low-risk patients, 2.43% 
(95% ci 1.23 to 3.92) in intermediate and 8.4% 
(95% ci 6.68 to 10.25) in high-risk patients.
Conclusions this meta-analysis demonstrates that hcM 
risk-scD provides accurate risk estimations that can be 
used to guide icD therapy in accordance with the 2014 esc 
guidelines.
registration number PrOsPerO crD42017064203;Pre-
results.
InTrOduCTIOn
Hypertrophic cardiomyopathy (HCM) is an inher-
ited cardiac condition associated with ventricular 
arrhythmias and sudden cardiac death (SCD).1 2 
Observational data indicate that prophylactic treat-
ment with implantable cardioverter defibrillators 
(ICD) can be life-saving but the selection of patients 
most likely to benefit remains the subject of debate. 
In 2014, the European Society of Cardiology (ESC) 
recommended a strategy based on the estimated risk 
of SCD derived from a validated risk prediction 
model, HCM Risk-SCD.2 3 Since publication of the 
2014 ESC guideline, several studies have assessed the 
performance of the ESC algorithm in different clin-
ical settings. The aim of this study was to systemati-
cally review the published literature and to measure 
the performance of the 2014 ESC guidelines by 
determining the observed prevalence of SCD in low, 




The systematic review was carried out in accor-
dance to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses amendment to the 
Quality of Reporting of Meta-analyses statement 
and Cochrane Collaboration and Meta-analysis of 
Observational Studies in Epidemiology guidelines. 
The systematic review protocol was registered with 
the International Prospective Register of Systematic 




All longitudinal observational cohort studies 
reporting SCD endpoints in patients with HCM were 
included, irrespective of setting. Studies which selec-
tively reported on patient subgroups (ie, based on 
specific treatments, diagnostic tests or phenotype), 
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Participants
HCM was diagnosed in the presence of left ventricular maximal 
wall thickness (MWT) ≥15 mm unexplained by abnormal loading 
conditions4 or in accordance with published criteria for diagnosis 
in relatives of patients with unequivocal HCM.5 Only studies 
examining adult patients (≥16 years of age) without prior ventric-
ular fibrillation or sustained ventricular tachycardia were included.
Intervention
The intervention under investigation was risk assessment using 
HCM Risk-SCD (http://www. doc2do. com/ hcm/ webHCM. 
html) which uses seven parameters (definitions in online 
supplementary material) to estimate the risk of SCD within 
5 years of clinical evaluation using the following equation3: 




where Prognostic Index = 0.15939858*maximal LV wall 
thickness (mm) − 0.00294271* maximal LV wall thickness2 
(mm2) +0.0259082* Left atrial diameter (mm) +0.00446131* 
LVOTgmax(mm Hg) +0.4583082*Family history of SCD 
(Yes=1/No=0) + 0.82639195*Non-sustained VT (Yes=1/No=0) 
+ 0.71650361*Unexplained syncope (Yes=1/No=0) − 0.01799934 
*Age (years).
Primary endpoint
The primary endpoint was SCD or an equivalent event. SCD was 
defined as witnessed sudden death with or without documented 
ventricular fibrillation or death within 1 hour of new symptoms 
or nocturnal deaths with no antecedent history of worsening 
symptoms.6 Aborted SCD during follow-up and appropriate 
ICD shock therapy were considered equivalent to SCD.7–12 As in 
previous studies, ICD shocks were considered appropriate if the 
treated tachyarrhythmia was ventricular in origin.7–12 Antitachy-
cardia pacing (ATP) was not considered as an equivalent to SCD. 
Since HCM Risk-SCD estimates the risk of sudden death within 
5 years of baseline evaluation, only SCD endpoints occurring 
within the initial 5 years of follow-up were considered.
Contact with authors
To reduce exclusion bias and minimise missing data, study 
authors of eligible studies were contacted to resolve uncertain-
ties and provide further data.
Information sources
PubMed was searched and the reference lists of reviews, letters 
and editorials were scrutinised for relevant material.
search strategy
The Medline search strategy was: (hypertrophic cardiomyopathy) 
AND death AND (‘2014/10/01’[PDat]: ‘2017/12/08’[PDat]). A 
priori the systematic review included the HCM Risk-SCD devel-
opment study.3 Only articles in English were included for the 
analysis and relevant titles in other languages were recorded.
study records
Data management
The initial literature search results were uploaded to EPPI-Re-
viewer V.4 which was used to manage the retrieved abstracts 
(https:// eppi. ioe. ac. uk/ cms/).
Selection process
The retrieved studies were independently reviewed at the title 
and/or abstract level for the inclusion and exclusion criteria. 
Full manuscripts were obtained for all reports meeting the 
inclusion criteria or when there was ambiguity. The full manu-
scripts were then reviewed to see if the inclusion criteria were 
satisfied. A detailed study of authors, dates and locations was 
used to reduce redundancy. The reviewers were not blinded 
to the journal titles or to the study authors or institution. 
Reasons for exclusion were documented.
Data collection process
Data were extracted from the full-length manuscripts and 
transcribed to a purpose-built relational database (Access, 
Microsoft). Demographic data and methodological character-
istics were collected. The number of patients in each of the 
following risk categories, as defined by the 2014 ESC guide-
lines,2 was recorded:
1. Low risk (ICD not recommended): predicted 5-year risk of 
SCD <4%.
2. Intermediate risk (ICD may be considered): predicted 5-year 
risk of SCD 4% to <6%.
3. High risk (ICD should be considered): predicted 5-year risk 
of SCD ≥6%.
SCD endpoints per risk group were extracted. All extracted 
data were verified independently by another author and disa-
greements were resolved by consensus. Variations in defini-
tions of predictors and SCD endpoints were recorded.
Primary outcome
The primary outcome was the prevalence SCD endpoints within 
5 years of baseline evaluation in low, intermediate and high-risk 
categories.
secondary outcome
The performance measures used to validate the HCM Risk-SCD 
model (C-index, D-statistic, calibration slope) were extracted 
from all included studies.
Assessing the methodological quality of the studies
The methodological quality of the studies was evaluated using 
the Newcastle-Ottawa Scale (NOS).13 Each study was judged 
on eight items, categorised into three groups: cohort selec-
tion, the comparability of the groups and the ascertainment of 
outcome. Stars were awarded for each item, with a maximum 
score of 9.
data analysis and synthesis
The study characteristics are presented descriptively. The 
pooled observed SCD endpoint prevalence per risk group 
predicted by the HCM risk model was estimated. The random 
effects method was used to pool the SCD prevalence after 
stabilising the variance by transforming the proportions using 
the Freeman-Tukey double arcsine method.14 The fixed effects 
method was also used as part of a secondary analysis. The final 
pooled results were back-transformed using Miller’s inverse 
transformation with the harmonic mean of the sample sizes.15 
Forest plots were generated to display the prevalence and 
corresponding 95% CIs for each study and the overall pooled 
estimates and their CIs.16 Heterogeneity between studies was 
assessed by performing Cochran’s Q test,17 and estimating 
the between-study variance of the estimates using the DerSi-
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Figure 1 Study selection. The flow chart shows each step of the systematic search to identify studies reporting SCD endpoints within 5 years of 
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Patients (n) 3675 706 623* 502 288† 3703
Centres (n) 6 2 5 1 1 14
Follow-up (years) 6.6±5 7.7±5.3 3.7 (2.2–5.1) 8.6±4.3 5.6±3.8 7.6±6.5
Annual SCD rate 0.8 0.77 0.8 NA NA 0.6
Age (years) 48±17 49±16 49±16 51±18 52±16 52±15
MWT (mm) 20±5 20±5 20±5 22±NA 20±5 20±4
LVOTg (mm Hg) 31±38 48±44 12 (7–34) 75±NA 28±41 33±7
LAd (mm) 44±8 45±8 42±7 46±NA 41±7 43±8
NSVT (%) 634 (17.3) 157 (22.2) 214 (34.3) 58 (11.6) 66 (22.9) 582 (15.7)
Syncope (%) 507 (13.8) 72 (10.2) 94 (15.1) 45 (9) 34 (11.8) 474 (12.8)
FHSCD (%) 886 (24.1) 141 (20) 71 (11.4) 52 (10.4) 40 (13.9) 620 (16.7)
Validation type Internal External External External External External
C-index (95% CI) 0.7 (0.68 to 0.72) 0.69 (0.57 to 0.82) 0.69 0.92 (0.89 to 0.95) 0.86 0.7 (0.68 to 0.72)
C-index methodology Uno R Survival ROC Harrell's C ROC curves SPSS Stata ROC Uno
Newcastle-Ottawa Score 8 8 7 8 7 8
Continuous variables are presented as mean±SD or median (25th–75th centiles). 
*32/623 patients were also reported in HCM Risk-SCD.
†9/288 patients had cardiac arrest prior to baseline evaluation.
FHSCD, family history of sudden cardiac death; HCM, hypertrophic cardiomyopathy; LAd, left atrial diameter; LVOTg: maximal instantaneous left ventricular outflow tract gradient 
at rest or Valsalva; MWT, maximal wall thickness; NA, not available; NSVT, non-sustained ventricular tachycardia; ROC, receiver operating characteristic; SCD, sudden cardiac 
death. 














Low-risk patients (<4%) 2110 469 414 387 227 1524
SCD endpoints in low-risk patients (%) 24 (1.1) 6 (1.3) 9 (2.2) 0 (0) 3 (1.3) 16 (1)
Intermediate-risk patients (4% to <6%) 487 113 99 39 29 326
SCD endpoints in intermediate-risk patients (%) 17 (3.5) 6 (5.3) 2 (2) 2 (5.1) 0 (0) 5 (1.5)
High-risk patients (>6%) 469 124 78 76 23 297
SCD endpoints in high-risk patients (%) 43 (9.2) 8 (6.5) 6 (7.7) 12 (15.8) 2 (8.7) 23 (7.7)
HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death. 
of the variation between studies due to heterogeneity rather 
than chance, and whether it impacted the conclusions of 
the meta-analyses, the heterogeneity was quantified by the 
I2 measure.20 The estimates of the between-study variance 
are presented on the scale of the transformed proportions. 
Heterogeneity between studies was also assessed visually by 
inspecting the Forest plots. Stata (V.14) was used to carry out 
the meta-analysis.
resuLTs
A total of 653 articles fulfilled the search criteria in PubMed 
and six retrospective observational studies21–26 were candi-
dates for the systematic review/meta-analysis (figure 1). One 
study included patients with a history of ventricular fibrilla-
tion and was included in the meta-analysis once the authors 
provided the required SCD endpoint data for patients without 
a history of cardiac arrest.26 Another study did not report 
SCD endpoints within 5 years of baseline evaluation; the 
authors were contacted but as data were not provided the 
study was excluded.22 The systematic review thus included 
five studies identified from the literature search21 23–26 and 
HCM Risk-SCD.3 All six studies involved subjects ≥16 years 
of age diagnosed either with conventional or familial criteria. 
The included studies are summarised in table 1. Excluded 
studies reporting on selected HCM subgroups and non-En-
glish publications are listed in online supplementary material.
estimation of 5-year risk of sCd and sCd endpoints
All included studies calculated the 5-year risk of SCD using 
the HCM Risk-SCD model equation and classified patients in 
the risk groups proposed by the 2014 ESC guidelines.3 21 23–26 
Uniform predictor definitions were used, except in one study23 
where family history of SCD was defined as HCM-related SCD 
in at least one first degree or other relatives ≤50 years and unex-
plained syncope had to be recent (≤5 years of baseline evalua-
tion). The same study used ATP as a surrogate of SCD23 but all 
other studies used the same SCD endpoint definition as stated in 
the Methods section.3 21 24 Following communication with the 
study authors, ATP endpoints (and 32 patients reported in both 
HCM Risk-SCD and Magrì et al23) were excluded.
sCd endpoints per sCd risk group
The included studies reported a total of 9456 unique patients 
without a history of cardiac arrest but due to missing data the 
5-year risk of SCD was not available in 2165 (23%) patients 
(in the original studies multiple imputation was used for these 
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Figure 2 SCD endpoints versus SCD risk category. The mosaic plot illustrates SCD endpoints for each SCD risk category in the 7291 subjects 
reported in the six included studies of the meta-analysis. The heights of the elements in each stacked bar indicate the percentage of those without 
SCD endpoints. The width of each stacked bar is proportional to the number of observations in each risk group; the areas of the elements also indicate 
absolute counts (also included in the figure). SCD, sudden cardiac death. 
individuals (5131 (70%) low risk; 1093 (15%) intermediate risk; 
1067 (15%) high risk) with 184 (2.5%) SCD endpoints within 5 
years of baseline evaluation. SCD endpoints per risk group are 
shown in table 2 and figure 2. High-risk patients contributed 
51% of SCD endpoints; 68% of all SCD endpoints occurred in 
patients with an estimated 5-year risk of ≥4% who formed 30% 
of the total study cohort.
Pooled sCd endpoint prevalence per 2014 esC risk group
Using the random effects method, the pooled prevalence of SCD 
endpoints was 1.0% (95% CI 0.52 to 1.61) in low-risk patients, 
2.43 (95% CI 1.23 to 3.92) in intermediate-risk patients and 
8.39 (95% CI 6.68 to 10.25) in high-risk patients (figure 3). 
Moderate heterogeneity was observed for the low-risk group 
with an I2 value of about 65%. Results were similar when a fixed 
effects method was used and the pooled prevalence of SCD 
endpoints was 1.01% (95% CI 0.74 to 1.32) in low-risk patients, 
2.39 (95% CI 1.46 to 3.48) in intermediate-risk patients and 
8.38 (95% CI 6.73 to 10.19) in high-risk patients.
Validation measures
The C-index, calculated with a variety of methods, ranged from 
0.69 to 0.92 as shown in table 1. Calibration slope and D-sta-
tistic were only reported in HCM Risk-SCD (calibration slope: 
0.91, 95% CI 0.74 to 1.08; D-statistic: 1.07, 95% CI 0.81 to 
1.32)3 and EVIDENCE-HCM (calibration slope: 1.02, 95% CI 
0.93 to 1.12; D-statistic: 1.17, 95% CI 1.05 to 1.29).25 The 
intercept of the calibration slopes was not reported.
Methodological quality of included studies
NOS ranged from 7 to 8 stars, out of a maximum of 9 (table 1). 
The detailed breakdown of NOS is shown in the online supple-
mentary material.
dIsCussIOn
This study analysed data from more than 7000 unselected 
patients with HCM from Europe, Asia, Middle East, North and 
South America, and the main findings support the 2014 ESC 
guideline recommendations for the primary prevention of SCD. 
Application of these guidelines in clinical practice facilitates 
targeted management of the subgroup of patients in whom ICD 
has the greatest potential to prevent SCD and allows reassurance 
for the large majority of patients who are at very low risk.
The effectiveness of ICD in preventing SCD in HCM is 
well established but frequent device complications27 make risk 
stratification a crucial step in the management of all patients. 
Historically, SCD risk has been estimated by evaluating clinical 
parameters which reflect the severity of the underlying myocar-
dial disease. This assessment is then used to guide clinical deci-
sion-making with respect to prophylactic ICD implantation. 
The first risk stratification strategy jointly proposed by the 
ESC and the American College of Cardiology (ACC) in 2003 
was an algorithm based on consensus and limited contempo-
raneous data, and relied on a simple phenotypic assessment to 
provide a qualitative evaluation of risk.28 A similar approach is 
currently recommended by the ACC and American Heart Asso-
ciation.1 The major limitation of these approaches is the depen-
dence on relative rather than absolute risk estimates to guide 
treatment. Furthermore, the phenotypic assessment is relatively 
crude in that all major risk factors are considered in a dichoto-
mous manner which can give rise to obvious clinical dilemmas; 
for example, it is improbable that an MWT of 29 mm confers a 
significantly different risk than 30 mm. To overcome these and 
other limitations,29 the 2014 ESC guidelines recommend a risk 
prediction model that provides individualised, quantitative prog-
nostic risk estimates using a more enhanced phenotypic assess-
ment based of seven clinical parameters previously shown to be 
associated with SCD.2 3
This meta-analysis summarises all available published data 
relevant to the 2014 ESC guideline performance for SCD preven-
tion. Patients in the prespecified high-risk and low-risk catego-
ries had the highest and lowest prevalences of SCD endpoints 
within 5 years of baseline evaluation, respectively, and pooled 
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Figure 3 Prevalence of sudden cardiac death (SCD) endpoints within 5 years of baseline evaluation. The Forest plots show the prevalence (%) and 
95% CIs with the random effects method for low (A), intermediate (B) and high-risk (C) patients. Patients with 5-year risk <4% are considered low 
risk and require systematic reassessment; intermediate-risk patients (5-year risk 4% to <6%) may be considered for an implantable cardioverter 
defibrillator (ICD) depending on comorbidities; high-risk patients (5-year risk ≥6%) should be considered for an ICD. The between-study variance was 
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findings support the ESC recommendation that patients with 
5-year risk <4% should be conservatively treated while those 
with an estimated 5-year risk ≥6% should be considered for an 
ICD.2 The intermediate risk group had a relatively low preva-
lence of SCD endpoints and the meta-analysis suggests that the 
risk in these patients is overestimated. However, since more than 
two-thirds of SCD endpoints occur in intermediate and high-risk 
patients, the pragmatic approach is to continue to target these 
patients for a primary prevention ICD.
All included studies examined the prognostic accuracy of 
HCM Risk-SCD using the C-index which is a measure of how 
well the model discriminates between patients with and without 
SCD.30 31 The reported C-indices consistently show that the 
model has good discrimination. Differences in the statistical 
methods used to derive the C-indices did not allow further 
exploration by pooling the data using meta-analysis and other 
validation measures were not consistently reported.
The included patient cohorts came from diverse geographic 
locations and healthcare settings but had similar clinical char-
acteristics and annual SCD rates. Most studies had a mean 
follow-up period of >5 years which is critical in examining the 
performance of the HCM Risk-SCD tool. Only patients with 
complete data to calculate the 5-year risk of SCD were included. 
Some patients were inevitably lost to follow-up within the first 
5 years of clinical evaluation which may lead to an underesti-
mation of SCD endpoint prevalence. Examining the observed 
5-year SCD rates rather than the prevalence of SCD within 5 
years would be more informative but these were not uniformly 
published.
Of the six studies identified by the literature search, only one 
was excluded as the number of SCD endpoints within 5 years 
of baseline evaluation was not provided.22 This study exam-
ined 1629 patients from two North American tertiary referral 
centres and suggested that the 2014 ESC guideline was unreli-
able as most SCD endpoints occurred in low-risk patients. These 
findings may be explained by an unaccounted change in risk 
profile beyond 5 years of baseline evaluation and by underes-
timation of risk due to missing data which are not reported.22 
Inclusion of this study is unlikely to have altered the results of 
this meta-analysis as the published prevalence of SCD endpoints 
during long-term follow-up (>5 years) was concordant with the 
predicted 5-year risk of SCD (SCD endpoint prevalence of 3.8% 
in low-risk and 12% in high-risk patients).22
Some studies were excluded from the systematic review 
because they reported on patient subgroups selected by specific 
therapeutic or diagnostic modalities. Four studies reported on 
ATP and appropriate ICD shocks in a small number of primary 
prevention ICD recipients, often without reporting events 
within 5 years.32–35 Two of these studies—which included a total 
of 154 patients—demonstrated that events were most prevalent 
in high-risk patients.32 34 Another study of 52 ICD recipients 
reported a higher mean estimated 5-year risk in patients who 
had therapies but a breakdown of events per ESC risk group was 
not provided.35 Rigopoulos et al investigated 32 ICD recipients 
who underwent percutaneous transluminal septal myocardial 
ablation and found that postprocedural appropriate ICD shocks 
occurred in patients with a high preprocedural risk.33 In another 
study of 844 patients who underwent percutaneous transluminal 
septal myocardial ablation, there was good agreement between 
observed and predicted SCD endpoints within 5 years of base-
line evaluation.36 Finally, in a study of 117 patients who under-
went a cardiac MRI, high and intermediate-risk patients had the 
highest prevalence of endpoints during long-term follow-up.37 
Reports excluded due to publication in non-English language 
were primarily reviews and thus unlikely to have an impact on 
the findings of the meta-analysis.
The meta-analysis also demonstrates the limitations of 
this approach and highlights the need for improvement. SCD 
endpoints in low-risk patients are the most obvious problem 
for individual patients and on the population level. This is not 
unique to HCM and it is well recognised that subgroups with the 
highest case fatality rates have the lowest population attributable 
risk and vice versa.38 Even though some events in the low-risk 
patients may relate to a change in clinical risk profile during 
follow-up which is not taken into consideration in this analysis, 
there is a clear need for improvement. Overestimation of risk in 
intermediate-risk patients should also be addressed. To improve 
risk prediction, the incremental value of other predictors needs 
to be systematically examined in appropriately powered cohort 
studies. Candidate predictors for future models include late 
gadolinium enhancement,37 39 mutations in sarcomeric protein 
genes40 41 and exercise testing-derived variables such as ventila-
tory efficiency (VE/VCO2) slope and abnormal blood pressure 
response to exercise.23 24 Future studies should first consider 
new predictors which are readily available at minimal cost and 
burden to the patient. Expensive and difficult to obtain predic-
tors should then be examined for their incremental value.42
COnCLusIOn
This meta-analysis examined SCD endpoints in more than 7000 
patients with HCM from around the world and the findings 
support the 2014 ESC guidelines on SCD. It demonstrates that 
low-risk patients can be treated conservatively as the prevalence 
of SCD endpoints within 5 years of evaluation is very low. The 
high prevalence of SCD endpoints in high-risk patients means 
that these patients should be considered for an ICD. The risk 
of SCD is overestimated in intermediate-risk patients, but as 
more than two-thirds of SCD endpoints occur in intermediate 
and high-risk patients, the pragmatic approach is to continue to 
target both these subgroups for a primary prevention ICD.
Key messages
What is already known on this subject?
 ► Hypertrophic cardiomyopathy (HCM) is an inherited cardiac 
condition associated with ventricular arrhythmias and 
sudden cardiac death (SCD). In 2014, the European Society 
of Cardiology (ESC) recommended a strategy based on the 
estimated risk of SCD derived from a validated risk prediction 
model, HCM Risk-SCD.
What might this study add?
 ► This meta-analysis of data from six studies involving 7291 
patients with HCM demonstrates that in most patients the 
observed prevalence of sudden death within 5 years of 
evaluation is concordant with the predicted risk.
how might this impact on clinical practice?
 ► The results support the risk stratification strategy proposed by 
the 2014 ESC guidelines which uses a risk prediction model 
(HCM Risk-SCD) to estimate the risk of SCD within 5 years of 
evaluation.
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